Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
暂无分享,去创建一个
R. James | J. Carmichael | P. Karásek | P. Rougier | D. Cunningham | J. Douillard | J. Carmichael | M. Navarro | A. Roth | P Rougier | M Navarro | L. Awad | J. Douillard | A. Roth | R. James | P. Jandík | T. Iveson | M. Alakl | G. Gruia | D Cunningham | J Carmichael | JY Douillard | AD Roth | RD James | P Karasek | P Jandik | T Iveson | M Alakl | G Gruia | L Awad | D. Cunningham
[1] M. Ychou,et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Köhne,et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[4] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[5] W. Hiddemann,et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Jäger,et al. High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study. , 1995, European journal of cancer.
[7] J. Dierlamm,et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] A. Norman,et al. Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] L. Påhlman,et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer , 1994, Cancer.
[10] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[11] L. Liu,et al. Topoisomerase-targeting antitumor drugs. , 1989, Biochimica et biophysica acta.
[12] K. Kohn,et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.
[13] R. Hertzberg,et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.
[14] D. Schoenfeld,et al. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. , 1982, Biometrics.
[15] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[16] J. Verweij,et al. Topoisomerase I inhibitors: topotecan and irenotecan. , 1994, Cancer treatment reviews.
[17] P. Piedbois. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Wittes,et al. Clinical drug development: an analysis of phase II trials, 1970-1985. , 1987, Cancer treatment reports.